Alnylam Pharmaceuticals EV/EBIT ALNY

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 27.9×
2-year median: 81.1×
Against its 2-year history: 5th; percentile: 0 is its lowest day, 100 its highest
2-year range: 25.5× to 357×
Peer median: 19.1×

Alnylam Pharmaceuticals' EV/EBIT is 27.9× as of Oct 23, 2026.

That is below its 2-year median of 81.1×, lower than on 95% of days in the last 2 years.

Over that time it ranged from 25.5× in Jul 2026 to 357× in Oct 2024.

The median for 10 biotech stocks of a similar size is 19.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.9×	25.5×	194×
2025	195×	193×	223×
2024	344×	296×	357×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
ALNYAlnylam Pharmaceuticals	27.9×
UTHRUnited Therapeutics	16.1×
INCYIncyte	10.1×
ONCBeOne Medicines	42.2×
EXELExelixis	15.4×
NBIXNeurocrine Biosciences	18.2×
HALOHalozyme Therapeutics	17.4×
TECHBIO-TECHNE	44.9×
REGNRegeneron Pharmaceuticals	20.0×
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
Peer median	19.1×

Where Alnylam Pharmaceuticals ranks

#12of 17Biotech stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.